A Trial Assessing Efficacy and Toxicity of a Combination of Rituximab and Lenalidomide (R2) vs Rituximab Alone as Maintenance After Chemoimmunotherapy With Rituximab-Bendamustine for Relapsed/Refractory FL Patients Not Eligible for ASCT
Phase of Trial: Phase III
Latest Information Update: 04 Jan 2018
At a glance
- Drugs Lenalidomide (Primary) ; Rituximab
- Indications Follicular lymphoma
- Focus Therapeutic Use
- Acronyms FIL_RENOIR12
- 28 Dec 2017 Planned End Date changed from 1 Sep 2019 to 1 May 2021.
- 28 Dec 2017 Planned primary completion date changed from 1 Jan 2017 to 1 Nov 2018.
- 28 Jul 2014 New trial record